February 27, 2023: NCHR urges Congress to support the decision by the Centers for
Medicare and Medicaid Services (CMS) to limit the coverage of newly approved Alzheimer’s
drugs until the treatments have been shown to have a meaningful, clinical benefit that outweighs
the risks for the Medicare population.
Author: Caroline Bradford
Lawmakers, advocates press for diversity in clinical trials
National Journal, February 15, 2023: NCHR joins lawmakers and other advocates in urging FDA and NIH to improve diversity in race/ethnicity, age, and sex in clinical trials as a way to improve medical care for everyone. So far, enforcement is lacking.
Read More »NCHR Comments on FDA update to “healthy” food label criteria
NCHR supports FDA’s updated criteria for the “healthy” food label focused on foods with high nutritional value and healthy eating patterns, rather than specific nutrients. However, we urge the agency to ensure the “healthy” label isn’t on foods that are highly processed, contain artificial sweeteners or are high in saturated fats. The revised definition will help consumers make informed food choices that will benefit their health.
Read More »Testimony of Dr. Diana Zuckerman before the House of Delegates Environment & Transportation Committee For HB 299
February 15, 2023: NCHR testified before the Maryland House Environment Committee to support HB299, which would require transparency about the use and disposal of artificial turf and infill. That will enable communities to make informed decisions about the environmental and health impact of these materials.
Read More »Testimony of Dr. Diana Zuckerman at CMS MEDCAC Meeting On Coverage with Evidence Development
February 13, 2023: In testimony before CMS MEDCAC, NCHR strongly supported the new proposals to improve the quality of research needed to decide Medicare coverage evidence. We especially appreciate the focus on clinically meaningful benefits for patients that are representative of Medicare beneficiaries
Read More »